Statements (40)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
antihypertensive agent potassium channel opener vasodilator |
| gptkbp:affiliatedWith |
benzothiadiazine class
|
| gptkbp:ATCCode |
C02DA01
|
| gptkbp:CASNumber |
364-98-7
|
| gptkbp:chemicalFormula |
C8H7ClN2O2S
|
| gptkbp:contraindication |
compensated heart failure
functional hypoglycemia hypersensitivity to diazoxide |
| gptkbp:discoveredBy |
gptkb:Bayer
|
| gptkbp:discoveredIn |
1960s
|
| gptkbp:eliminationHalfLife |
21-45 hours
|
| gptkbp:excretion |
renal
|
| https://www.w3.org/2000/01/rdf-schema#label |
diazoxide
|
| gptkbp:IUPACName |
7-chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
|
| gptkbp:KEGGID |
D00318
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
opens ATP-sensitive potassium channels
|
| gptkbp:meltingPoint |
230-232 °C
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:molecularWeight |
230.67 g/mol
|
| gptkbp:pregnancyCategory |
C
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1427
3016 DB01119 |
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
hypotension
tachycardia hyperglycemia fluid retention |
| gptkbp:synonym |
Hyperstat
Proglycem |
| gptkbp:UNII |
GFO928U08A
|
| gptkbp:usedFor |
treatment of hypertensive emergencies
treatment of hypoglycemia |
| gptkbp:bfsParent |
gptkb:insulinoma
|
| gptkbp:bfsLayer |
6
|